JP2022527081A5 - - Google Patents
Info
- Publication number
- JP2022527081A5 JP2022527081A5 JP2021557377A JP2021557377A JP2022527081A5 JP 2022527081 A5 JP2022527081 A5 JP 2022527081A5 JP 2021557377 A JP2021557377 A JP 2021557377A JP 2021557377 A JP2021557377 A JP 2021557377A JP 2022527081 A5 JP2022527081 A5 JP 2022527081A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- intracellular
- cancer
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025024834A JP2025081512A (ja) | 2019-03-26 | 2025-02-19 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824080P | 2019-03-26 | 2019-03-26 | |
| US62/824,080 | 2019-03-26 | ||
| US201962931103P | 2019-11-05 | 2019-11-05 | |
| US62/931,103 | 2019-11-05 | ||
| US202062969569P | 2020-02-03 | 2020-02-03 | |
| US62/969,569 | 2020-02-03 | ||
| PCT/US2020/025069 WO2020198531A2 (en) | 2019-03-26 | 2020-03-26 | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025024834A Division JP2025081512A (ja) | 2019-03-26 | 2025-02-19 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527081A JP2022527081A (ja) | 2022-05-30 |
| JP2022527081A5 true JP2022527081A5 (https=) | 2023-04-03 |
Family
ID=72610137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557377A Pending JP2022527081A (ja) | 2019-03-26 | 2020-03-26 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
| JP2025024834A Pending JP2025081512A (ja) | 2019-03-26 | 2025-02-19 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025024834A Pending JP2025081512A (ja) | 2019-03-26 | 2025-02-19 | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230312708A1 (https=) |
| EP (1) | EP3953372A4 (https=) |
| JP (2) | JP2022527081A (https=) |
| KR (1) | KR20210143804A (https=) |
| CN (1) | CN113710688A (https=) |
| AU (1) | AU2020248448B2 (https=) |
| CA (1) | CA3134465A1 (https=) |
| IL (1) | IL286618A (https=) |
| MX (1) | MX2021011494A (https=) |
| SG (1) | SG11202110131SA (https=) |
| WO (1) | WO2020198531A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024505093A (ja) * | 2021-02-01 | 2024-02-02 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 神経内分泌がんの治療 |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| EP4523704A1 (en) | 2022-05-12 | 2025-03-19 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Camptothecin derivative and ligand-drug conjugate |
| US12600801B2 (en) * | 2022-07-11 | 2026-04-14 | Fred Hutchinson Cancer Center | Single-domain antibodies that bind ROR1 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025079987A2 (ko) * | 2023-10-10 | 2025-04-17 | 서울대학교산학협력단 | 키메라 항원 수용체를 발현하는 자연 살해 세포를 이용한 종양 미세환경의 주피세포를 표적하는 항암 세포 치료 기법 및 치료 효능 평가를 위한 종양 미세환경 오가노이드 모델 제작 기술 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| ES2702315T3 (es) * | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| WO2016016344A1 (en) * | 2014-07-29 | 2016-02-04 | Cellectis | Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy |
| US20170333480A1 (en) * | 2014-11-05 | 2017-11-23 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| ES2818103T3 (es) * | 2015-01-16 | 2021-04-09 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos para ROR1 |
| US20190048085A1 (en) * | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| BR112019006781A2 (pt) * | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| CN108424458A (zh) * | 2017-02-13 | 2018-08-21 | 上海恒润达生生物科技有限公司 | 靶向ny-eso-1的嵌合抗原受体及其用途 |
| AU2018289581C1 (en) * | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| WO2021102055A1 (en) * | 2019-11-18 | 2021-05-27 | The Regents Of The University Of California | Anti-ror-2 antibodies and methods of use |
-
2020
- 2020-03-26 AU AU2020248448A patent/AU2020248448B2/en active Active
- 2020-03-26 JP JP2021557377A patent/JP2022527081A/ja active Pending
- 2020-03-26 CA CA3134465A patent/CA3134465A1/en active Pending
- 2020-03-26 US US17/598,200 patent/US20230312708A1/en active Pending
- 2020-03-26 MX MX2021011494A patent/MX2021011494A/es unknown
- 2020-03-26 EP EP20778519.7A patent/EP3953372A4/en active Pending
- 2020-03-26 SG SG11202110131SA patent/SG11202110131SA/en unknown
- 2020-03-26 WO PCT/US2020/025069 patent/WO2020198531A2/en not_active Ceased
- 2020-03-26 KR KR1020217032699A patent/KR20210143804A/ko not_active Ceased
- 2020-03-26 CN CN202080028702.4A patent/CN113710688A/zh active Pending
-
2021
- 2021-09-23 IL IL286618A patent/IL286618A/en unknown
-
2025
- 2025-02-19 JP JP2025024834A patent/JP2025081512A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527081A5 (https=) | ||
| JP2025081512A5 (https=) | ||
| JP7106594B2 (ja) | Ｐｄ－ｌ１に対するヒト抗体 | |
| JP7575100B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| Chu et al. | Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells | |
| JP2022116230A (ja) | 免疫療法用改変細胞 | |
| KR20240073008A (ko) | Cd137 및 종양 연관 항원에 결합하는 이중특이적 결합 단백질 | |
| IL264144B2 (en) | Antibody 18A2 against CLAUDIN and its use | |
| JP2022528030A5 (https=) | ||
| Schlereth et al. | Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3 | |
| JP2022542559A5 (https=) | ||
| JP2022513372A5 (https=) | ||
| JP2022521240A5 (https=) | ||
| JP2019536469A5 (https=) | ||
| US20240400705A1 (en) | Composition of recombinant antigen binding molecules and method of making and using thereof | |
| JP2022548112A5 (https=) | ||
| US20250161358A1 (en) | Modified immune effector cells and uses thereof | |
| JP2024505093A5 (https=) | ||
| WO2025238157A1 (en) | Multispecific binding agent suitable for use in cancer immune therapy | |
| Burns | The Major Clinical Components of Cancer Immunotherapy (Modulating Cell-Mediated Immune Mechanisms) | |
| WO2023016554A1 (zh) | 靶向cd22的抗原结合蛋白及其用途 | |
| KR20250089551A (ko) | 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법 | |
| AU2024217219A1 (en) | Function-enhanced cell therapy | |
| NZ735778A (en) | Kappa myeloma antigen chimeric antigen receptors and uses thereof | |
| NZ721656B2 (en) | Human antibodies to pd-l1 |